Search the Newsreel

Emergent BioSolutions faces securities probe after $191M NARCAN impairment and $97M adjusted EBITDA report

Emergent BioSolutions is facing a securities probe by Levi & Korsinsky law firm following a reported $191.3 million non-cash impairment on its NARCAN product and a subsequent decline in its stock. The company's Q2 revenue was $234 million with $97 million in adjusted EBITDA, …

Veranda Learning Q1FY27 net profit up 471% to ₹339 crore; guides ₹670 crore revenue

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

Contineum Therapeutics (CTNM), Disc Medicine (IRON), and Recursion Pharmaceuticals (RXRX) are making PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign …

Got $200? 1 Quantum Computing ETF to Buy Right Now.

If you have $200 and want to point it at something that feels like the future, Defiance Quantum ETF (NASDAQ: QTUM) is a serious contender instead of a science project. When you buy this ETF, you're buying a basket of companies that are already …

Universal Technical Institute cuts FY2026 EBITDA outlook, shares drop sharply amid investigation.

Universal Technical Institute (UTI) has reduced its fiscal year 2026 adjusted EBITDA forecast from over $155 million to above $135 million, leading to a significant drop in its stock price. The company attributed this cut to lower-than-expected enrollment in its high-school auto and diesel …

Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales Guidance - And What's Next

Tarsus Pharmaceuticals (TARS) saw its stock rise by 6.8% after reporting strong Q2 2026 results and raising its 2026 XDEMVY net product sales guidance to US$685 million–US$705 million. This increased confidence in XDEMVY's commercial trajectory supports the company's near-term revenue, though risks related to …

Summit Therapeutics (NASDAQ:SMMT) Hits New 1-Year Low - Here's Why

Summit Therapeutics (NASDAQ:SMMT) shares recently hit a new 52-week low, trading at approximately $12.20, below both their 50-day and 200-day moving averages. This drop follows lowered analyst price targets, a consensus "Hold" rating, and the company narrowly missing quarterly earnings estimates with a loss …

United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript

NRX Pharmaceuticals earnings missed by $0.33, revenue fell short of estimates

NRX Pharmaceuticals (NASDAQ: NRXP) reported its second-quarter earnings, missing analyst estimates for both EPS and revenue. The company posted an EPS of $-0.440, significantly worse than the $-0.113 estimate, and revenue of $1.1M, falling short of the $1.75M consensus. Despite the miss, the stock …

Loss of China Rights for Jing Zhu Da Might Change The Case For Investing In Syndax (SNDX)

Why Cardiol Therapeutics Inc Class A stock is gaining today

Jacobs nabs MMSD committee backing, pledges to cut Palantir. What next?

An ad hoc committee has recommended Jacobs Solutions as the next wastewater operator for the Milwaukee Metropolitan Sewerage District (MMSD), passing over the current operator, Veolia. Jacobs secured this backing after pledging to terminate its partnership with Palantir, a controversial software company. This decision …

Cantor Fitzgerald Downgrades Eyepoint Pharmaceuticals (NASDAQ:EYPT) to Neutral

Cantor Fitzgerald downgraded Eyepoint Pharmaceuticals (NASDAQ:EYPT) from an "overweight" to a "neutral" rating, causing shares to fall by $10.59 to $4.16, near its 52-week low. Despite the downgrade, the consensus among analysts remains a "Moderate Buy" with a target price of $44.38. The company …

Consensus Cloud Solutions (NASDAQ:CCSI) Stock Price Down 6.2% Following Insider Selling

Consensus Cloud Solutions (NASDAQ:CCSI) experienced a 6.2% stock price drop after CTO Jeffrey Alan Sullivan sold 5,400 shares, reducing his direct stake by 4.49%. Despite this insider selling, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of …

Dermata Therapeutics raises $3.4 million in private placement

Dermata Therapeutics (NASDAQ:DRMA) has announced a private placement offering expected to generate approximately $3.4 million in gross proceeds. The offering includes common stock or pre-funded warrants, along with series E and F warrants, priced at $1.46 per share. Company insiders are also participating, and …

DA Davidson reiterates PDF Solutions stock rating on eProbe growth

DA Davidson has reiterated a Buy rating and a $74.00 price target for PDF Solutions Inc. (NASDAQ:PDFS), citing strong demand for the company's eProbe tool and expectations for continued growth. The firm's analysis follows a visit to PDF Solutions' San Jose facility, where they …

The Quantum Race Is Heating Up—And 2 Small Players Stand Out

Quantum Computing Inc. (QUBT) and Infleqtion Inc. (INFQ), two smaller quantum technology companies, have reported strong revenue growth but are grappling with rapidly increasing operating expenses and losses. While larger player IonQ has distinguished itself with strong performance and strategic acquisitions, D-Wave Quantum fell …

Universal Technical Institute (UTI) Securities Investigation Notice - Levi & Korsinsky

Levi & Korsinsky is investigating Universal Technical Institute (NYSE: UTI) after the company lowered its fiscal Q3 2026 adjusted EBITDA outlook to $135 million from $155 million, causing a sharp drop in share prices. The reduction is largely attributed to weaker-than-expected fourth-quarter starts in …

EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate

EyePoint Pharmaceuticals (EYPT) shares plummeted after its wet AMD treatment, Duravyu, failed its primary endpoint in a Phase 3 trial, putting the stock on track for a 16-month low. In contrast, rival Ocular Therapeutix (OCUL) saw its shares surge as its SOL-1 Phase 3 …

PTGX Maintained by BMO Capital -- Price Target Raised to $178

BMO Capital has maintained its 'Outperform' rating for Protagonist Therapeutics Inc (PTGX) and significantly raised its price target from $112.00 to $178.00. Despite this positive analyst sentiment, GuruFocus indicates PTGX is 76.8% overvalued with a GF Value™ of $87.75, and its GF Score™ of …

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

Figure Technology CFO Minchung Kgil Sells 4,000 Shares

Minchung Kgil, Chief Financial Officer of Figure Technology Solutions, Inc. (NASDAQ:FIGR), disposed of 4,000 shares of Class A Common Stock on Aug. 12, 2026. SEC Form 4 filing Transaction summary Metric Value Transaction value $120,120 Shares sold 4,000 Post-transaction shares (directly held) 491,651 Post-transaction …

Why Medicenna Therapeutics Corp stock surged yesterday

Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models

Xtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer (mCSPC) who are maintaining treatment with a GnRH analogue. Global sales for Xtandi® …

Stifel reiterates Tango Therapeutics stock rating with $40 target

Stifel has reaffirmed its Buy rating for Tango Therapeutics Inc. (NASDAQ:TNGX) with a price target of $40.00, despite the stock appearing overvalued relative to its Fair Value estimate. The firm anticipates positive longer follow-up data from an upcoming ESMO 2026 presentation regarding the company's …

EYPT Stock Slips As Insider Plans Share Sale

EyePoint Pharmaceuticals (EYPT) stock has dropped significantly following news of an insider's plan to sell securities, as indicated by an amended Form 144/A filing. While the company has a strong balance sheet with substantial cash reserves and a recent multi-week price climb, the insider …

Form 8K Eyepoint Pharmaceuticals Inc For: 17 August By Investing.com

This article reports on the filing of a Form 8K by Eyepoint Pharmaceuticals Inc. on August 17th. The brief piece includes the stock symbol EYPT, which is noted to be down 68.88%. No further details about the content of the Form 8K are provided.

Eyepoint Pharmaceuticals stock hits 52-week low at $4.06 By Investing.com

Eyepoint Pharmaceuticals Inc. (EYPT) stock recently hit a 52-week low of $4.06, despite a 33% increase over the past year. Analysts maintain a bullish outlook with an average price target suggesting a 58% upside. The company recently announced stockholder approval for an increase in …

EYPT Maintains Buy Rating by Chardan Capital -- Price Target Set at $65

Chardan Capital maintained its Buy rating for EyePoint Pharmaceuticals (EYPT) with a price target of $65.00, despite the stock being significantly overvalued according to GuruFocus's GF Value™ of $0.36 versus its current price of $14.76. The company also received a low GF Score™ of …

Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, BMO Capital Markets Analyst Says

Viavi Solutions (VIAV) Could Be 29% Undervalued As Vertex 6.0 Debuts

Viavi Solutions (VIAV) recently launched Vertex 6.0, an industry-first channel emulator for 6G and Wi-Fi 7/8 testing, coinciding with strong price momentum. Despite a recent market rerating, Simply Wall St suggests the stock is 29.1% undervalued based on its narrative fair value of $61.43, …

NRx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

NRx Pharmaceuticals announced its financial results for Q2 2026, highlighting significant progress towards FDA approval and commercialization of preservative-free ketamine, with an anticipated launch in 2026. The company also secured non-dilutive funding for NRX-101 trials and expanded its clinical footprint, reporting a net loss …

Canaccord Genuity Group Issues Positive Forecast for Cardiol Therapeutics (NASDAQ:CRDL) Stock Price

Fulcrum (NASDAQ: FULC) investors get cash but small stake post‑Slate deal

Definium Therapeutics (DFTX) Is Down 5.6% After Positive Phase 3 GAD Data For DT120 ODT

Is Brookfield Wealth Solutions (BNT) Fully Priced On Mixed Second Quarter Results?